A synthetic fragment of growth-hormone-releasing hormone that was once an approved drug for children with growth hormone deficiency.
Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone, the shortest fragment that keeps full activity. It stimulates the pituitary to release growth hormone.
The manufacturer discontinued Geref in 2008. There is currently no marketed FDA-approved sermorelin product. GHRH analogs are prohibited in sport under WADA rules.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
Sermorelin was approved in the 1990s as Geref, for diagnosing and treating growth hormone deficiency in children. Evidence for adult anti-aging or body-composition use is limited to small studies.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.